Benitec Biopharma Ltd., of Sydney, Australia, said its subsidiary, Tacere Therapeutics Inc., submitted an application to the National Institutes of Health's Recombinant DNA Advisory Committee (RAC), comprising the full clinical trial protocol for its ddRNAi-based therapeutic, TT-034, in hepatitis C virus infection, as well as safety and toxicology data

NeuroDerm Ltd., of Ness Ziona, Israel, said enrollment of patients is ongoing in its Phase IIa clinical trial of ND0612, a treatment for Parkinson's disease

clinical trials, for SMD and dry age-related macular degeneration (dry AMD...NeuroDerm Ltd., of Ness Ziona, Israel, said enrollment of patients is ongoing in its Phase IIa clinical trial of ND0612, a treatment for Parkinson's disease

Company (Location) Product Description Indication Status Date AUTOIMMUNE Trophos SA (Marseille, France) Olesoxime A mitochondrial-targeted, cholesterol-like compound Multiple sclerosis Started a Phase Ib study 3/15/13 CANCER Anaeropharma Science Inc. (Tokyo) APS001F A living recombinant bifidobacterium Advanced or metastatic solid tumors Started a Phase I trial 3/29/13 Bio-Path Holdings Inc. (Houston) BP-100-1.01 Liposomal Grb-2 Blood cancers Started enrolling patients in the fifth dosage

Company (Location) Product Description Indication Status Date AUTOIMMUNE Halozyme Therapeutics Inc. (San Diego) and Baxter International Inc. (London) HyQvia Combination of human normal immunoglobulin and recombinant human hyaluronidase designed as a replacement therapy Primary and secondary immunodeficiencies Received a positive opinion from the EMA's CHMP 3/25/13 Biogen Idec Inc. (Weston, Mass.) Tecfidera Dimethyl fumarate Relapsing-remitting multiple sclerosis Received a positive opinion

Company (Location) Product Description Indication Status Date AUTOIMMUNE Anacor Pharmaceuticals Inc. (Palo Alto, Calif.) AN2728 Topical boron-based phosphodiesterase-4 inhibitor Mild to moderate atopic dermatitis Phase II data showed it achieved a 71% improvement from baseline 3/22/13 GeNeuro SA (Geneva) GNbAC1 A humanized monoclonal antibody targeting a human endogenous retrovirus Multiple sclerosis Completed a Phase IIa study 3/15/13 CANCER Biothera Inc. (Eagen, Minn.) Imprime PGG Immuno

Bristol-Myers Squibb Co., of New York, will invest $250 million to expand its large-scale biologics manufacturing facility in Devens, Mass., introducing biologics development and clinical trial manufacturing capabilities and adding about 350 employees

Company (Location) Product Description Indication Status Date AUTOIMMUNE Anthera Pharmaceuticals Inc. (Hayward, Calif.) Blisibimod A peptibody antagonist of BAFF Lupus Started a Phase III trial 3/29/13 Biogen Idec Inc. (Weston, Mass.) Plegridy Peginterferon beta-1a Relapsing-remitting multiple sclerosis Two-year Phase III data showed it significantly reduced MS disease activity, including relapses, disability progression and brain lesions, compared to placebo at one year 3/21/13 Celgene Corp

Proceeds from the IPO would be used to fund clinical trials, R&D for additional AAT indications, expanding distribution capabilities to additional territories, expanding its manufacturing infrastructure and for general corporate purposes

And at the opening press conference, where scientists announced the results of several clinical trials of immunotherapies, discussant Louis Weiner, of Washington University in St. Louis, went so far as to suggest that immunotherapy should be considered a fourth branch of cancer therapy, along with surgery, radiation and drug treatment...And so, Topalian and her team are planning a clinical trial that will explicitly test sequential treatment with epigenetic-targeting drugs and PD-1 blockade

Coronado plans to use the proceeds to fund R&D, clinical trials and manufacture of supply as well as other corporate purposes

Mills noted that the company has gained "experience with not only the drug for its effects, but also in manufacturing multiple lots for our clinical trials," so Acadia is "very comfortable with the chemical characteristics of the drug

Alongside the Phase II evidence of safety and efficacy in glioblastoma, Activartis has evidence from academic clinical trials demonstrating the technology is applicable to other tumor types

The company plans to use the funds to move its lead program into clinical trials and to advance a second discovery program

S-TARget is seeking scientific advice from Germany's Paul-Ehrlich-Institut on clinical trial design

Alongside the Phase II evidence of safety and efficacy in glioblastoma, Activartis has evidence from academic clinical trials demonstrating the technology is applicable to other tumor types

That program is not yet in clinical trials

S-TARget is seeking scientific advice from Germany's Paul-Ehrlich-Institut on clinical trial design

Alongside the Phase II evidence of safety and efficacy in glioblastoma, Activartis has evidence from academic clinical trials demonstrating the technology is applicable to other tumor types